Enfuvirtide acetate
(Synonyms: 醋酸恩夫韦地; T20 acetate; DP178 acetate) 目录号 : GC38109A peptide inhibitor of HIV-1 fusion
Cas No.:914454-00-5
Sample solution is provided at 25 µL, 10mM.
Enfuvirtide is a biomimetic peptide inhibitor of HIV-1 fusion with CD4+ cells.1 It inhibits HIV-1 infectivity of HeLa cells stably expressing CD4 by the HXB2 strain (IC50 = 692 pM) and by clinical isolates (IC90s = 6.1-61 nM) in a single-cycle infectivity assay. It also inhibits genomic integration of HIV-1 into human intraepithelial vaginal cells and peripheral blood mononuclear cells (PBMCs; IC50s = 51.2 and 13.58 μM, respectively).2 Enfuvirtide binds to a recombinant molecular mimic of HIV-1 glycoprotein gp41 that contains three N-terminal heptad and two C-terminal heptad repeat regions (Kd = 32 nM).3 It also binds to recombinant formyl peptide receptors (FPR) expressed in rat basophilic leukemia cells (IC50 = 5 nM) and attracts and activates human peripheral blood phagocytes, but not T lymphocytes, in vitro when used at a concentration of 100 nM.4 Formulations containing enfuvirtide have been used in combination therapy for the treatment of HIV-1/AIDS.
1.Ingallinella, P., Bianchi, E., Ladwa, N.A., et al.Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potencyProc. Natl. Acad. Sci. USA106(14)5801-5806(2009) 2.McElrath, M.J., Ballweber, L., Terker, A., et al.Ex vivo comparison of microbicide efficacies for preventing HIV-1 genomic integration in intraepithelial vaginal cellsAntimicrob. Agents Chemother.54(2)763-772(2010) 3.Champagne, K., Shishido, A., and Root, M.J.Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coilJ. Biol. Chem.284(6)3619-3627(2009) 4.Sun, S.B., Gong, W.H., Gao, J.L., et al.T20/DP178, an ectodomain peptide of human immunodeficiency virus type 1 gp41, is an activator of human phagocyte N-formyl peptide receptorBlood93(11)3885-3892(1999)
Cas No. | 914454-00-5 | SDF | |
别名 | 醋酸恩夫韦地; T20 acetate; DP178 acetate | ||
分子式 | C206H305N51O66 | 分子量 | 4551.93 |
溶解度 | DMSO : 100 mg/mL (21.97 mM; Need ultrasonic); H2O : 2 mg/mL (0.44 mM; Need ultrasonic) | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 0.2197 mL | 1.0984 mL | 2.1969 mL |
5 mM | 0.0439 mL | 0.2197 mL | 0.4394 mL |
10 mM | 0.022 mL | 0.1098 mL | 0.2197 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet